HOME >> MEDICINE >> NEWS
Lexapro receives FDA approval for the treatment of generalized anxiety disorder

NEW YORK, December 18 - Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Lexapro (escitalopram oxalate), a selective serotonin reuptake inhibitor (SSRI), for the treatment of generalized anxiety disorder (GAD), a condition that affects approximately four million Americans annually. The new indication is based on three studies, all of which were positive and support the efficacy and safety of Lexapro in the treatment of GAD. GAD is characterized by excessive anxiety and worry that significantly impacts an individual's daily functioning. Lexapro is also indicated for the initial treatment and maintenance of major depressive disorder.

"One of the biggest challenges in treating GAD patients is finding a treatment that is not only effective, but also one that patients will be able to tolerate for the long term," said Philip Ninan, M.D., professor of Psychiatry and Behavioral Sciences and director of the Mood and Anxiety Disorders Program at Emory University School of Medicine. "Lexapro is a first-line treatment option, which has proven to be effective with a favorable side effect profile."

Study Details

All three studies that support the indication approval were randomized, double-blind, eight weeks in duration and placebo-controlled. The studies involved approximately 850 patients, 18 to 80 years of age, diagnosed with GAD. Patients in the Lexapro arm were administered a fixed dose of 10 mg per day for the first four weeks and then flexibly dosed to a maximum of 20 mg per day. The Hamilton Anxiety Scale (HAMA) total score was the primary efficacy variable, and secondary efficacy measures included changes in HAMA psychic anxiety subscale and Clinical Global Impressions (CGI) scores. In each of the three studies, Lexapro 10 to 20 mg per day significantly improved GAD symptoms in patients compared to placebo as measured by change from baseline in HAMA score. By-visit anal
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
18-Dec-2003


Page: 1 2

Related medicine news :

1. Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:3/28/2015)... a bite of warm, gooey pepperoni pizza, and your ... stomach, ready to break down your meal. In many ... amok, triggering a burning sensation in the chest. Heartburn ... Americans have heartburn at least once a month. The ... can be stopped. , Heartburn or acid reflux symptoms ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... March 27, 2015 /CNW/ - Covalon Technologies Ltd. (the ... company, today announced the issuance of an aggregate of ... Company and an aggregate of 120,500 stock options to ... will vest over three years and will be exercisable ... price of $1.40 per stock option. About ...
(Date:3/27/2015)... CITY , March 27, 2015 Dynatronics Corporation ... Linder has been appointed to the Company,s Board of ... by the death in November 2014 of board member ... Rich Linder to our Board of Directors represents an ... Jr. , chairman and president of Dynatronics.  "Rich is a ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
Cached News: